Bioelectronics Corp (BIEL)

[clk5192]

Something to consider--

Over the last eight years, there have been five instances where trading volume has been greater than 150 million for at least three consecutive days:

20Feb-03Mar 14 from $.0005 to $.0062/share
09-15Oct15 from $.002 to .0009/share
03Feb-02Mar17 from .0005 to .0012/share
04-08Jan18 from .0009 to .0008/share
Thursday through today from .002 to .0034/share

https://www.nasdaq.com/symbol/biel/historical

I bring this up because we are in unchartered territory here and the numbers prove it. In 2014 when the stock went up 12 fold, the product didn't have FDA approval. Three of those five have come within the last year. Those three have also coincided with some kind of news that was of value. The 20Feb14 jump coincided with the FDA reclassification of the Actipatch to a Class II. The money will come from the general clearance and numbers for the end of the quarter.

That being said, I do not buy the importance of sales or news or anything that comes from the UK, specifically B.Braun or NHS (see Bielcorp news from 14Jan15 and 26Nov14). If that were the case, it wouldn't have taken 3.5 years to get any kind of progress made and then the question becomes if the company was focused on UK with little to gain, where was the effort on the US front? That doesn't even include all of the news coming from Eastern Europe and Asia. The money will be made off of the USFDA and actual, tangible progress here in the US, not from our friends across the pond. Now if BIEL opens in the London Stock Exchange? Then, I'll take serious notice. Granted, we are only 30 days into NHS, so I could be completely wrong. We'll see when figures come out for Q2.